The prevalence of metabolic syndrome in drug-naïve bipolar II disorder patients before and after twelve week pharmacological intervention

Mei Hung Chi, Hui Hua Chang, Nian Sheng Tzeng, San Yuan Huang, Kuei-Ru Chou, Hsin Chun Tsai, Yen Kuang Yang, Ru Band Lu, See Po Chen

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Accumulating evidence indicates a high prevalence rate of metabolic disturbance in bipolar disorder (BP) patients. However, the prevalence across BP subtypes has been investigated to a lesser degree. In the current study, we surveyed the prevalence of metabolic syndrome among drug-naïve bipolar II patients. Moreover, the effects of pharmacological treatment on metabolic indexes were also evaluated. Methods: This study recruited fifty-six drug-naïve BP II patients diagnosed according to the DSM-IV criteria. Among them, forty-four patients completed a 12-week pharmacological intervention with valproic acid, fluoxetine and lorazepam. Metabolic profiles and body mass index (BMI) were measured at baseline and 2 weeks, 8 weeks, and 12 weeks after receiving medication. Results: The mean age of the 56 patients was 30.3±11.1. Before receiving medication, 6.5% of the patients met the ATP III criterion for metabolic syndrome. Among the 44 patients who completed the 12-week pharmacological intervention, the prevalence of metabolic syndrome increased from 7% to 10%. Repeated measurements showed that the changes in metabolic indexes were not significant, with the exceptions of BMI, waist circumference, and buttock circumference. In addition, the interaction between the improvement of hypomanic symptoms and BMI change was significant. Limitations: The study was limited by the follow-up duration and sample size. Conclusions: In drug-naïve BP II patients, the prevalence of metabolic syndrome was significantly lower than that observed before in BP I patients. However, medications use was also associated with an increased risk of metabolic disturbance, although the impact was lesser. Clinical evidence suggests that metabolism and emotion homeostasis might share common mechanisms.

Original languageEnglish
Pages (from-to)79-83
Number of pages5
JournalJournal of Affective Disorders
Volume146
Issue number1
DOIs
Publication statusPublished - Mar 20 2013

Fingerprint

Bipolar Disorder
Pharmacology
Pharmaceutical Preparations
Body Mass Index
Lorazepam
Buttocks
Metabolome
Fluoxetine
Valproic Acid
Waist Circumference
Diagnostic and Statistical Manual of Mental Disorders
Sample Size
Emotions
Homeostasis
Adenosine Triphosphate

Keywords

  • Bipolar disorder
  • Body mass index
  • Metabolic syndrome

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

The prevalence of metabolic syndrome in drug-naïve bipolar II disorder patients before and after twelve week pharmacological intervention. / Chi, Mei Hung; Chang, Hui Hua; Tzeng, Nian Sheng; Huang, San Yuan; Chou, Kuei-Ru; Tsai, Hsin Chun; Yang, Yen Kuang; Lu, Ru Band; Chen, See Po.

In: Journal of Affective Disorders, Vol. 146, No. 1, 20.03.2013, p. 79-83.

Research output: Contribution to journalArticle

Chi, Mei Hung ; Chang, Hui Hua ; Tzeng, Nian Sheng ; Huang, San Yuan ; Chou, Kuei-Ru ; Tsai, Hsin Chun ; Yang, Yen Kuang ; Lu, Ru Band ; Chen, See Po. / The prevalence of metabolic syndrome in drug-naïve bipolar II disorder patients before and after twelve week pharmacological intervention. In: Journal of Affective Disorders. 2013 ; Vol. 146, No. 1. pp. 79-83.
@article{457113866ee04a5e89574061c5272c9c,
title = "The prevalence of metabolic syndrome in drug-na{\"i}ve bipolar II disorder patients before and after twelve week pharmacological intervention",
abstract = "Background: Accumulating evidence indicates a high prevalence rate of metabolic disturbance in bipolar disorder (BP) patients. However, the prevalence across BP subtypes has been investigated to a lesser degree. In the current study, we surveyed the prevalence of metabolic syndrome among drug-na{\"i}ve bipolar II patients. Moreover, the effects of pharmacological treatment on metabolic indexes were also evaluated. Methods: This study recruited fifty-six drug-na{\"i}ve BP II patients diagnosed according to the DSM-IV criteria. Among them, forty-four patients completed a 12-week pharmacological intervention with valproic acid, fluoxetine and lorazepam. Metabolic profiles and body mass index (BMI) were measured at baseline and 2 weeks, 8 weeks, and 12 weeks after receiving medication. Results: The mean age of the 56 patients was 30.3±11.1. Before receiving medication, 6.5{\%} of the patients met the ATP III criterion for metabolic syndrome. Among the 44 patients who completed the 12-week pharmacological intervention, the prevalence of metabolic syndrome increased from 7{\%} to 10{\%}. Repeated measurements showed that the changes in metabolic indexes were not significant, with the exceptions of BMI, waist circumference, and buttock circumference. In addition, the interaction between the improvement of hypomanic symptoms and BMI change was significant. Limitations: The study was limited by the follow-up duration and sample size. Conclusions: In drug-na{\"i}ve BP II patients, the prevalence of metabolic syndrome was significantly lower than that observed before in BP I patients. However, medications use was also associated with an increased risk of metabolic disturbance, although the impact was lesser. Clinical evidence suggests that metabolism and emotion homeostasis might share common mechanisms.",
keywords = "Bipolar disorder, Body mass index, Metabolic syndrome",
author = "Chi, {Mei Hung} and Chang, {Hui Hua} and Tzeng, {Nian Sheng} and Huang, {San Yuan} and Kuei-Ru Chou and Tsai, {Hsin Chun} and Yang, {Yen Kuang} and Lu, {Ru Band} and Chen, {See Po}",
year = "2013",
month = "3",
day = "20",
doi = "10.1016/j.jad.2012.08.042",
language = "English",
volume = "146",
pages = "79--83",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - The prevalence of metabolic syndrome in drug-naïve bipolar II disorder patients before and after twelve week pharmacological intervention

AU - Chi, Mei Hung

AU - Chang, Hui Hua

AU - Tzeng, Nian Sheng

AU - Huang, San Yuan

AU - Chou, Kuei-Ru

AU - Tsai, Hsin Chun

AU - Yang, Yen Kuang

AU - Lu, Ru Band

AU - Chen, See Po

PY - 2013/3/20

Y1 - 2013/3/20

N2 - Background: Accumulating evidence indicates a high prevalence rate of metabolic disturbance in bipolar disorder (BP) patients. However, the prevalence across BP subtypes has been investigated to a lesser degree. In the current study, we surveyed the prevalence of metabolic syndrome among drug-naïve bipolar II patients. Moreover, the effects of pharmacological treatment on metabolic indexes were also evaluated. Methods: This study recruited fifty-six drug-naïve BP II patients diagnosed according to the DSM-IV criteria. Among them, forty-four patients completed a 12-week pharmacological intervention with valproic acid, fluoxetine and lorazepam. Metabolic profiles and body mass index (BMI) were measured at baseline and 2 weeks, 8 weeks, and 12 weeks after receiving medication. Results: The mean age of the 56 patients was 30.3±11.1. Before receiving medication, 6.5% of the patients met the ATP III criterion for metabolic syndrome. Among the 44 patients who completed the 12-week pharmacological intervention, the prevalence of metabolic syndrome increased from 7% to 10%. Repeated measurements showed that the changes in metabolic indexes were not significant, with the exceptions of BMI, waist circumference, and buttock circumference. In addition, the interaction between the improvement of hypomanic symptoms and BMI change was significant. Limitations: The study was limited by the follow-up duration and sample size. Conclusions: In drug-naïve BP II patients, the prevalence of metabolic syndrome was significantly lower than that observed before in BP I patients. However, medications use was also associated with an increased risk of metabolic disturbance, although the impact was lesser. Clinical evidence suggests that metabolism and emotion homeostasis might share common mechanisms.

AB - Background: Accumulating evidence indicates a high prevalence rate of metabolic disturbance in bipolar disorder (BP) patients. However, the prevalence across BP subtypes has been investigated to a lesser degree. In the current study, we surveyed the prevalence of metabolic syndrome among drug-naïve bipolar II patients. Moreover, the effects of pharmacological treatment on metabolic indexes were also evaluated. Methods: This study recruited fifty-six drug-naïve BP II patients diagnosed according to the DSM-IV criteria. Among them, forty-four patients completed a 12-week pharmacological intervention with valproic acid, fluoxetine and lorazepam. Metabolic profiles and body mass index (BMI) were measured at baseline and 2 weeks, 8 weeks, and 12 weeks after receiving medication. Results: The mean age of the 56 patients was 30.3±11.1. Before receiving medication, 6.5% of the patients met the ATP III criterion for metabolic syndrome. Among the 44 patients who completed the 12-week pharmacological intervention, the prevalence of metabolic syndrome increased from 7% to 10%. Repeated measurements showed that the changes in metabolic indexes were not significant, with the exceptions of BMI, waist circumference, and buttock circumference. In addition, the interaction between the improvement of hypomanic symptoms and BMI change was significant. Limitations: The study was limited by the follow-up duration and sample size. Conclusions: In drug-naïve BP II patients, the prevalence of metabolic syndrome was significantly lower than that observed before in BP I patients. However, medications use was also associated with an increased risk of metabolic disturbance, although the impact was lesser. Clinical evidence suggests that metabolism and emotion homeostasis might share common mechanisms.

KW - Bipolar disorder

KW - Body mass index

KW - Metabolic syndrome

UR - http://www.scopus.com/inward/record.url?scp=84874517529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874517529&partnerID=8YFLogxK

U2 - 10.1016/j.jad.2012.08.042

DO - 10.1016/j.jad.2012.08.042

M3 - Article

VL - 146

SP - 79

EP - 83

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

IS - 1

ER -